<DOC>
	<DOC>NCT01078090</DOC>
	<brief_summary>Observation of safety, tolerability and effectiveness of adalimumab (Humira) therapy in a large patient collective under everyday clinical conditions over a 5-year period.</brief_summary>
	<brief_title>Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice</brief_title>
	<detailed_description>Patients with Rheumatoid Arthritis and started treatment with adalimumab in a normal clinical setting according to the label were documented. The follow-up observation period was for 5 years and focused on safety information and maintenance of efficacy during the normal clinical setting. Follow-up with participants was via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate to severe active rheumatoid arthritis in adults with insufficient response to diseasemodifying antirheumatic drugs, including methotrexate. Moderate to severe active rheumatoid arthritis in adults who have not been treated with methotrexate before. In case of incompatibility with methotrexate, adalimumab can be used as monotherapy Hypersensitivity against the drug or one of the other ingredients; active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections); moderate to severe cardiac insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Effectiveness</keyword>
</DOC>